期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿托伐他汀钙软胶囊溶出度的测定 被引量：3

Determination on dissolution of Atorvastatin Calcium Soft Capsules
下载PDF
导出
摘要 目的建立阿托伐他汀钙软胶囊溶出度的测定方法.方法以磷酸盐缓冲液(pH7.4)900ml为溶出介质,采用转篮法(100r?min-1)45min取样,运用HPLC法对其溶出度进行测定,并考察了溶出曲线.结果样品溶出均一性良好,溶出度均>90%.结论本法能考察和控制阿托伐他汀钙软胶囊的质量. OBJECTIVE A method was established about determining the dissolution of Atorvastatin Calcium Soft Capsules. METHODS The phosphate buffer solution（pH7. 4） was used as the dissolution medium and rotary basket method was also used（100r·min^-1） . The samples was determined after 45 mins. The dissolution content was determined by HPLC. The dissolution curve was discussed. RESULTS The dissolution homogeneity of three batches of samples was good and dissolution contents were all above 90 percent. CONCLUSION This method can control the quality of Atorvastatin Calcium Soft Capsules.
作者 孙瑜 张文 毛学建 黄选波
机构地区 天津中医药大学 山东省立医院 济南中信医药有限公司 济南海泰医药科技有限公司
出处 《齐鲁药事》 2006年第12期737-739,共3页 qilu pharmaceutical affairs
关键词 阿托伐他汀钙软肢囊 溶出度 HPLC Atorvastatin Calcium Soft Capsules dissolution HPLC
分类号 R917 [医药卫生—药物分析学]
  • 相关文献

参考文献5

二级参考文献17

  • 1Saito S,Takayama T,Honye J,et al.Effect of lipid-lowering therapy on plaque volume and composition in patient with coronary artery disease evaluated by three dimensional intravascular ultrasound[J].中国循环杂志,2002,11(17):143.
  • 2Tgre-Aminou G,Van Vliet AK,Vliet AK,et al.Inhibition of proliferation of human smooth muscle cues by various HMG-coA reductase inhibitors;comparison with other human ceu types[J].Biochem Biophys Acta,1997,1345(3):259-268.
  • 3Nwrocki JW,Weiss SR,Davidson MH,et al.Reduction of LDL-cholesterol by 25% to 60% in patients with dyspeptic primary hy percholesterolemia by atorvastatin.A new HMG-coA reductase inhibitor[J].Arterioscler Thromb Vasc Boil,1995,15:678-683.
  • 4Jones PH,Kafone KS,Iaurora I,et al.Comparative does efficacy study of atorvastatin versus simvastatin,pravastatin,lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study )[J].Am J Cardiol,1998,81(5):582.
  • 5Lea AP,McTavish D.Atorvastatin a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias[J].Drugs,1997,53(5):828-847.
  • 6Bakker-Arkema RG,Best J,Fayyad R,et al.A brief review paper of the efficacy and safety of atorvastatin in early clinical trials[J].Atherosclerosis,1997,131(1):17-23.
  • 7Funatsn T,Kakuta H,Tanaka H,et al.Atorvastatin(lipitor);a review of its pharmacological and clinical profile[J].Nippon Yakurigaku Zasshi,2001,117(1):65.
  • 8Bakkev-Arkema RG,Davidson MH,Goldstein RT,et al.Efficacy and safety of a new HMG-coA reductase inhibitor,atorvastatin,in patients with hypertriglyceridemia[J].Jam Med Assoc,1996,275(2):128-133.
  • 9Yess Hs,Fayyad R,Bertolini G,et al.Application of atorvastatin in treating original and mixture hyperlipidema[J].Ahn Pharmacother,1998,32(10):1030-1043.
  • 10Marais AD,Frith JC,Bereman M,et al.Atobastatin is powerful and agent fir lowering plasma cholesterol concentration in heterozygous familial hypereholesterolemia[J].Atherosclerlsis,1994,109(1-2):316.

共引文献28

同被引文献19

引证文献3

二级引证文献4

齐鲁药事
2006年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部